Real-world cost-effectiveness of cetuximab in the third-line treatment of metastatic colorectal cancer based on patient chart review in the Netherlands

Carin Uyl - de Groot; Ellen Rooijen; CJA Punt; CP Pescott

doi:10.1186/s13561-018-0197-3

Real-world cost-effectiveness of cetuximab in the third-line treatment of metastatic colorectal cancer based on patient chart review in the Netherlands

Carin Uyl - de Groot
, Ellen Rooijen
, CJA Punt
, CP Pescott

Research output: Contribution to journal › Article › Academic › peer-review

9 Citations (Scopus)

41 Downloads (Pure)

Original language	Undefined/Unknown
Pages (from-to)	13
Journal	Health Economics Review
Volume	8
Issue number	1
DOIs	https://doi.org/10.1186/s13561-018-0197-3
Publication status	Published - 2018

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Research programs

EMC NIHES-05-63-02 Quality

Access to Document

10.1186/s13561-018-0197-3

Repub_115464_O-A.pdfFinal published version, 828 KB

http://hdl.handle.net/1765/115464

Cite this

@article{1265d3c012314712a318cba28af13c74,

title = "Real-world cost-effectiveness of cetuximab in the third-line treatment of metastatic colorectal cancer based on patient chart review in the Netherlands",

author = "\{Uyl - de Groot\}, Carin and Ellen Rooijen and CJA Punt and CP Pescott",

year = "2018",

doi = "10.1186/s13561-018-0197-3",

language = "Undefined/Unknown",

volume = "8",

pages = "13",

journal = "Health Economics Review",

issn = "2191-1991",

publisher = "BioMed Central Ltd.",

number = "1",

}

TY - JOUR

T1 - Real-world cost-effectiveness of cetuximab in the third-line treatment of metastatic colorectal cancer based on patient chart review in the Netherlands

AU - Uyl - de Groot, Carin

AU - Rooijen, Ellen

AU - Punt, CJA

AU - Pescott, CP

PY - 2018

Y1 - 2018

U2 - 10.1186/s13561-018-0197-3

DO - 10.1186/s13561-018-0197-3

M3 - Article

C2 - 30019286

SN - 2191-1991

VL - 8

SP - 13

JO - Health Economics Review

JF - Health Economics Review

IS - 1

ER -